Benutzerspezifische Werkzeuge

Klinische Studien

Klinische Studien

Für Patienten

In unserem Studienzentrum liegt der Schwerpunkt auf Studien der Phase II und III.

  • aktuelle klinische Studien zu folgenden Indikationen:
Prostatakarzinom

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with
Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer

CheckMate 7DX

A confirmatory, prospective, open-label, single-arm, reader-blinded, multi-centre phase 3 study to assess the diagnostic accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and unenhanced MRI in reference to histopathology in newly-diagnosed prostate cancer (PCA) patients, scheduled for radical prostatectomy (RP) wih extended pelvic lymph node dissection (ePLND)

SPL-01-001

A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

ADAM

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

AMPLITUDE
Urothelkarzinom (Harnblase)

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC)

Keynote-866

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer

Keynote-B15
Urothelkarzinom (Harnblase und oberer Harntrakt)

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

THOR

Phase III Study of Sacituzumab Govitecan in Metastatic or Locally Advanced Unresectable Urothelial Cancer

IMMU-132-13
Nierenzellkarzinom

A Phase II, Multicentre, Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Clear-Cell Variant Renal Cell Carcinoma Who Progressed After 1st Line Treatment with Checkpoint Inhibitors

Cabopoint

weitere Informationen finden Sie unter: ClinicalTrials.gov

Sofern Sie in diesem Zusammenhang Fragen haben oder eventuell an einer der Studien in unserer Klinik teilnehmen möchten, setzen Sie sich bitte mit uns in Verbindung.

Kontakt:

Platzhalter Bild

Pit Raupach

Studienkoordinator

+49- 0351 458-4425 +49- 0351 458-7280